MetrioPharm Press Releases
-
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
FDA grants orphan drug designation for MetrioPharm's lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD).
-
MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
MP1032 has many advantages over other available antivirals: it can be conveniently administered orally and has both anti-inflammatory and anti-Sars-CoV-2 properties, making it an ideal candidate to prevent a so-called cytokine storm.
-
MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)
DMD is classified as an orphan (rare) disease of high unmet medical need. New treatments for orphan diseases receive priority support during development and market authorization from the EMA and the US FDA.
-
Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19
The objective of the study is to determine whether treatment with MetrioPharm’s lead compound MP1032 can slow the spread of the virus and alleviate COVID-19 symptoms in recently hospitalized patients.In preclinical trials the compound had shown both antiviral and anti-inflammatory properties.
-
MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19
The objective of the study is to determine whether the anti-inflammatory effect of MP1032 can slow the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease and alleviate COVID-19 symptoms.
-
MetrioPharm Signs European Commission Grant Agreement for €7.9 Million
The project includes the conduct of a Phase II clinical trial with MetrioPharm’s lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2.
-
MetrioPharm Doses First Patient in Phase II Study of MP1032 in COVID-19
The study’s target is to determine if MP1032's anti-inflammatory effect can slow down the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease 2019, as well as alleviate COVID-19 symptoms.
-
MetrioPharm AG Strengthens Equity by CHF 27.5 M
MetrioPharm AG announces that two convertible loans granted by shareholders in the total amount of CHF 18.5 million have been converted to equity. The equity was increased by a further CHF 9 million through the exercise of subscription rights in two cash capital increases.
-
Thomas Christély joins management of MetrioPharm AG as CEO
Thomas Christély to start as CEO of MetrioPharm AG on October 1, 2021. Dr. Wolfgang Brysch will accelerate expansion of clinical development as CSO & CMO.
-
MetrioPharm Selected by European Commission for Funding as Part of the "HERA Incubator”
European Commission nominates MetrioPharm with Covid project "iMPact" to the list of HERA funded projects